SG11202005239YA - Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration - Google Patents

Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Info

Publication number
SG11202005239YA
SG11202005239YA SG11202005239YA SG11202005239YA SG11202005239YA SG 11202005239Y A SG11202005239Y A SG 11202005239YA SG 11202005239Y A SG11202005239Y A SG 11202005239YA SG 11202005239Y A SG11202005239Y A SG 11202005239YA SG 11202005239Y A SG11202005239Y A SG 11202005239YA
Authority
SG
Singapore
Prior art keywords
methods
botulinum toxin
response rate
high response
effect duration
Prior art date
Application number
SG11202005239YA
Inventor
Roman Rubio
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of SG11202005239YA publication Critical patent/SG11202005239YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
SG11202005239YA 2017-12-04 2018-12-04 Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration SG11202005239YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762594529P 2017-12-04 2017-12-04
US201862774850P 2018-12-03 2018-12-03
PCT/US2018/063942 WO2019113133A1 (en) 2017-12-04 2018-12-04 Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Publications (1)

Publication Number Publication Date
SG11202005239YA true SG11202005239YA (en) 2020-07-29

Family

ID=66750627

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005239YA SG11202005239YA (en) 2017-12-04 2018-12-04 Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Country Status (15)

Country Link
US (1) US20200384090A1 (en)
EP (1) EP3720475A4 (en)
JP (1) JP2021505570A (en)
KR (1) KR20200105829A (en)
CN (1) CN111655279A (en)
AU (1) AU2018378465A1 (en)
BR (1) BR112020011098A2 (en)
CA (1) CA3084175A1 (en)
CO (1) CO2020008231A2 (en)
IL (1) IL275032A (en)
MX (1) MX2020005785A (en)
PH (1) PH12020550821A1 (en)
RU (1) RU2020121540A (en)
SG (1) SG11202005239YA (en)
WO (1) WO2019113133A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869373B (en) 2009-06-25 2017-05-10 雷文斯治疗公司 albumin-free botulinum toxin formulations
JP2020520917A (en) * 2017-05-18 2020-07-16 ルバンス セラピュティックス インク.Revance Therapeutics,Inc. How to treat cervical dystonia
MX2022014564A (en) * 2020-06-05 2022-12-15 Merz Pharma Gmbh & Co Kgaa High dose and low volume botulinum toxin treatment of facial wrinkles.
WO2022081736A1 (en) * 2020-10-13 2022-04-21 Revance Therapeutics, Inc. Methods for treating cervical dystonia
AU2022223782A1 (en) * 2021-02-21 2023-09-21 Revance Therapeutics, Inc. Methods of and compositions for treatment of upper limb spasticity
CN113432267A (en) * 2021-06-29 2021-09-24 哈尔滨蛐宝科技有限公司 Intelligent air disinfection control method and device based on wifi
KR20240047418A (en) * 2021-08-12 2024-04-12 이온 바이오파마, 인크. Disposable neurotoxin formulation and packaging

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007136616A (en) * 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) COMPOSITION AND METHOD FOR LOCAL USE AND PERFORMANCE OF BOTULIN TOXIN
NZ568216A (en) * 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
SG10202100698QA (en) * 2008-12-31 2021-02-25 Revance Therapeutics Inc Injectable Botulinum Toxin Formulations
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
CA2970136C (en) * 2014-12-08 2023-07-04 JJSK R&D Pte Ltd Carrier molecule compositions and related methods
KR20180077202A (en) * 2015-10-29 2018-07-06 레반스 테라퓨틱스, 아이엔씨. Injectable botulinum toxin preparations and methods using these with long-lasting therapeutic or cosmetic effects

Also Published As

Publication number Publication date
RU2020121540A (en) 2022-01-10
WO2019113133A1 (en) 2019-06-13
US20200384090A1 (en) 2020-12-10
BR112020011098A2 (en) 2020-11-17
KR20200105829A (en) 2020-09-09
IL275032A (en) 2020-07-30
JP2021505570A (en) 2021-02-18
CO2020008231A2 (en) 2020-08-10
CA3084175A1 (en) 2019-06-13
RU2020121540A3 (en) 2022-04-27
CN111655279A (en) 2020-09-11
MX2020005785A (en) 2020-10-28
AU2018378465A1 (en) 2020-07-09
PH12020550821A1 (en) 2021-05-10
EP3720475A1 (en) 2020-10-14
EP3720475A4 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
IL286472A (en) Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
IL275032A (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
GB2582482B (en) CASZ compositions and methods of use
HK1247238B (en) Engineered crispr-cas9 compositions and methods of use
HK1256608A1 (en) Flavonoid compositions and methods of use
EP3402549A4 (en) Microneedle compositions and methods of using same
GB2582100B (en) CAS12C Compositions and methods of use
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
HK1252567A1 (en) Substituted benzamides and methods of use thereof
ZA201906169B (en) Synthekine compositions and methods of use
ZA201900044B (en) Tuberculosis compositions and methods of treating or preventing tuberculosis
IL280690A (en) Pharmaceutical compositions comprising dgla and use of same
ZA201804380B (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
HK1247136A1 (en) Compositions comprising 15-hepe and methods of using the same
IL259970A (en) Methods and compositions of insect control
PT3503885T (en) Pharmaceutical composition and methods of uses
IL250852A0 (en) Periodontal composition and method of use
EP3703738A4 (en) Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect
IL260321B (en) Multi-antigen construct and pharmaceutical composition comprising same
GB201617161D0 (en) Insect repelient composition and method of use
GB2562322B (en) Furniture unit and method of use thereof
GB201720981D0 (en) Improved rail and method of use thereof